New hope for brain metastases? drug duo targets advanced cancers
NCT ID NCT05700721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, niraparib and dostarlimab, can control advanced cancers that have spread to the brain. It includes 120 adults with certain cancer types like BRCA-mutated or lung cancers. The goal is to see if the treatment shrinks or stabilizes brain tumors, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BRCA1/2M CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Can a 3D camera make brain radiation safer and more precise?
- Experimental drug combo targets Hard-to-Treat lung cancer
- Pinpoint radiation may spare the brain in lung cancer that spreads